Serum alpha fetoprotein (AFP) is a “gold-standard”
biomarker for the diagnosis of hepatocellular carcinoma (HCC). Available
pieces of evidence suggest that the ratio of AFP-L3 isoform in the
total AFP may provide more accurate prediction for the incidence of
HCC. In this work, we design an electrochemical aptasensor for high-accuracy
assay of AFP-L3 ratio based on differentiated labeling of AFP isoforms
in an orderly fashion. Specifically, total AFP is first captured by
an AFP aptamer-functionalized electrode and labeled with quantum dots-functionalized
DNA probes via mild reduction. Then, AFP-L3 isoform that strongly
binds to Lens culinaris agglutinin is labeled with
silver nanoparticles after the exonuclease-catalyzed removal of DNA
probes. By tracing the electrochemical responses of quantum dots and
silver nanoparticles, respectively, the amounts of total AFP and AFP-L3
isoforms are determined and the AFP-L3 ratio is accordingly calculated
to favor the accurate HCC diagnosis. Experimental results prove the
high-accuracy assay of AFP-L3 ratio based on the AFP quantitation
in a linear range of 0.0008–40 ng mL–1 and
AFP-L3 quantitation in a linear range of 0.004–40 ng mL–1. The aptasensor also displays satisfactory specificity
and good recoveries even in the complex serum samples. Therefore,
the aptasensor may provide a valuable tool for the assay of the AFP-L3
ratio and have a great potential use in early warning of HCC for clinical
application.
To identify phenotype of aggressive breast cancer (BC) cells is vital for the effectiveness of surgical intervention and standard-of-care therapy. HER-2 is overexpressed in aggressive BC and MMP-2 is a...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.